Viking Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Viking Therapeutics, Inc. (VKTX) had Debt Securities, Available-for-sale, Amortized Cost of $376.62 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-07-29
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $376.62M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $485.25M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $539.09M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $613.33M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $376.62M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $485.25M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $539.09M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $613.33M 10-Q · filed 2025-10-23 |
| 2025-06-30 | $773.53M 10-Q · filed 2025-07-23 |
| 2025-03-31 | $813.63M 10-Q · filed 2025-04-24 |
| 2024-12-31 | $876.21M 10-K · filed 2026-02-11 |
| 2024-09-30 | $878.12M 10-Q · filed 2024-10-23 |
| 2024-06-30 | $900.27M 10-Q · filed 2024-07-24 |
| 2024-03-31 | $768.61M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $306.66M 10-K · filed 2025-02-26 |
| 2023-09-30 | $339.60M 10-Q · filed 2023-10-25 |
| 2023-06-30 | $324.16M 10-Q · filed 2023-07-26 |
| 2023-03-31 | $117.64M 10-Q · filed 2023-04-26 |
| 2022-12-31 | $119.69M 10-K · filed 2024-02-07 |
| 2022-09-30 | $126.98M 10-Q · filed 2022-10-26 |
| 2022-06-30 | $154.16M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $173.89M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $176.28M 10-K · filed 2023-02-10 |
| 2021-09-30 | $205.04M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $219.62M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $224.98M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $219.32M 10-K · filed 2022-02-09 |
| 2020-09-30 | $251.48M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $243.88M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $254.71M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $267.25M 10-K · filed 2021-02-17 |
| 2019-09-30 | $256.96M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $273.27M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $284.42M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $277.16M 10-K · filed 2020-02-26 |
| 2018-09-30 | $134.77M 10-Q · filed 2018-11-07 |
| 2017-12-31 | $11.61M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |